Hospital de Móstoles-ko ikertzaileekin lankidetzan egindako argitalpenak (15)

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2017

  1. Eradication of hepatitis C virus and non-liver-related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection

    Hepatology, Vol. 66, Núm. 2, pp. 344-356

2015

  1. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus

    Clinical Infectious Diseases, Vol. 60, Núm. 6, pp. 950-958

2014

  1. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 280-287

2013

  1. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus

    Journal of Hepatology, Vol. 58, Núm. 6, pp. 1104-1112

2012

  1. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with hiv and hepatitis c virus

    Clinical Infectious Diseases, Vol. 55, Núm. 5, pp. 728-736

2011

  1. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 12, pp. 2843-2849

2008

  1. Efectos secundarios graves derivados de las interacciones medicamentosas del tratamiento antirretroviral

    Revista Clinica Espanola, Vol. 208, Núm. 11, pp. 557-560

  2. New CCR5 inhibitor antiretroviral drugs and integrase inhibitors

    Revista Clinica Espanola, Vol. 208, Núm. 9, pp. 463-466

2005

  1. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors

    Journal of Antimicrobial Chemotherapy, Vol. 55, Núm. 5, pp. 800-804

2004

  1. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects

    Vaccine, Vol. 22, Núm. 23-24, pp. 2966-2973

2002

  1. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999

    Sexually Transmitted Infections, Vol. 78, Núm. 4, pp. 255-260

  2. Tratamiento antirretroviral inicial

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 20, Núm. SUPPL.2, pp. 3-9

1996

  1. ESTUDIO TRANSVERSAL MULTIHOSPITALARIO DE TUBERCULOSIS Y RESISTENCIAS EN MADRID (OCTUBRE DE 1993-ABRIL DE 1994)

    Medicina Clinica, Vol. 106, Núm. 1, pp. 1-6

1989

  1. Visceral leishmaniasis (Kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in spain

    Reviews of Infectious Diseases, Vol. 11, Núm. 4, pp. 655-660